Michael A Bookman

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi First-line chemotherapy in epithelial ovarian cancer
    Michael A Bookman
    University of Arizona Cancer Center, Tucson, Arizona, USA
    Clin Obstet Gynecol 55:96-113. 2012
  2. ncbi Trials with impact on clinical management: first line
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Int J Gynecol Cancer 19:S55-62. 2009
  3. ncbi The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    M A Bookman
    Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    Ann Oncol 21:vii211-17. 2010
  4. ncbi Update of randomized trials in first-line treatment
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Ann Oncol 22:viii52-viii60. 2011

Detail Information

Publications4

  1. ncbi First-line chemotherapy in epithelial ovarian cancer
    Michael A Bookman
    University of Arizona Cancer Center, Tucson, Arizona, USA
    Clin Obstet Gynecol 55:96-113. 2012
    ..Encouraging data have emerged using antiangiogenic agents, but with questions regarding optimal timing and patient selection. The use of 3-drug combinations or maintenance chemotherapy is not supported...
  2. ncbi Trials with impact on clinical management: first line
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Int J Gynecol Cancer 19:S55-62. 2009
    ..Emerging data from these trials need to be interpreted within an evolving paradigm of cancer biology, disease management, and availability of clinical resources...
  3. ncbi The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    M A Bookman
    Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    Ann Oncol 21:vii211-17. 2010
    ..Emerging biological paradigms will hopefully contribute to individualized treatment options in the future...
  4. ncbi Update of randomized trials in first-line treatment
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Ann Oncol 22:viii52-viii60. 2011
    ..Ongoing and planned trials will evaluate the inhibition of DNA repair and tailored treatment in accordance with tumor molecular profiles...